Analytical Data
-
Gene name
LIV-1/SLC39A6
- Application
-
Alternative Names
SLC39A6; LIV-1; ZIP6; Zinc transporter ZIP6; ZIP-6
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-hFc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13433-1
-
Expression Region
F29-W325
-
Molecular Weight
80-95 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
LIV-1, also known as SLC39A6, is a member of the solute carrier family of transporters, specifically functioning as a zinc transporter. Initially identified in the context of breast cancer, LIV-1 has garnered significant attention due to its upregulation in various malignancies, including prostate and pancreatic cancers. Its role in cellular zinc homeostasis is critical, as zinc is an essential micronutrient that influences numerous biological processes, including cell proliferation, apoptosis, and DNA repair. The aberrant expression of LIV-1 can disrupt zinc balance, contributing to tumor progression and metastasis. Research has demonstrated that LIV-1 not only aids in tumor cell survival but may also play a role in angiogenesis and immune response evasion. The interest in recombinant LIV-1 protein arises from its potential to serve as a biomarker for cancer diagnosis and prognosis, as well as a therapeutic target. By characterizing the structure and function of LIV-1, researchers aim to elucidate its mechanistic pathways, which may lead to the development of novel therapeutic strategies. Furthermore, understanding LIV-1's interaction with zinc and its influence on tumor microenvironments could provide valuable insights into cancer biology. As such, continued investigation of LIV-1/SLC39A6 will enhance our understanding of its role in cancer and contribute to the advancement of targeted therapies aimed at improving patient outcomes.
